StudyFinder
MT2016-11 :Autologous Stem Cell Transplant In Patients with Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)
Status: Recruiting
The treatment (chemotherapy and transplant procedures) is considered standard clinical care that are usually given to the patients with this disease. The research aspect of this study is to collect data on the patients who are being treated on this plan. Patients will be followed throughout the course of their clinical care and for three years after their transplant.
Sex: Male or Female
Age Group: Not specified
Inclusion Criteria:
• up to 75 years of age
• diagnosis of Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Mature B cell Lymphoma, or Mature T cell Lymphoma
• at least 4 weeks from previous chemotherapy; 6 weeks from nitrosoureas
• women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment
• see link to clinicaltrials.gov for complete criteria
Exclusion Criteria:
• women who are pregnant or breastfeeding
• chemotherapy resistant disease
• unrelated active infection
Interventions:
Drug: AraC, Drug: BCNU, Drug: Cyclophosphamide, Drug: Etoposide, Biological: G-CSF, Drug: Melphalan, Procedure: Peripheral blood stem cell transplantation, Radiation: Total Body Irradiation
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Study Contact: Veronika Bachanova - bach0173@umn.edu
Principal Investigator: Veronika Bachanova, MD
Phase: PHASE2
IRB Number: 1611M99805
See this study on ClinicalTrials.gov